We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Gilead Sciences (NASDAQ:GILD – Get Free Report) had its price target hoisted by equities researchers at Morgan Stanley from $123.00 to $130.00 in a research note issued to investors on ...

Gilead Sciences (NASDAQ:GILD – Free Report) had its price target raised by Oppenheimer from $115.00 to $132.00 in a report ...

COVID-19, and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California. For more information on Gilead Sciences, please visit the company’s ...

Your FREE insider update on the biggest news stories and investing trends, delivered midday TheChart of the Day belongs to ...

The EU drugs regulator says Gilead Sciences’ antiviral drug remdesivir should be made available for people seriously ill with COVID-19, despite limited data on its efficacy. The EMA’s human ...

Gilead Sciences, Inc. today announced the presentation of late-breaking data and multiple oral presentations from its innovative HIV treatment portfolio and pipeline at the Conference on Retroviruses ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Gilead Sciences Inc. (NASDAQ: GILD ... including Veklury sales of $1.4 billion, which is its COVID-19 treatment. 2) Gilead’s HIV, Oncology, and Liver Disease Franchise Continues to Grow In 2024, ...

On March 11 2020, as COVID continued to spread rapidly around the globe, the World Health Organization (WHO) officially ...

Gilead Sciences Inc. GILD stock surged to a new ... including Veklury sales of $1.4 billion, which is its COVID-19 treatment. 2) Gilead’s HIV, Oncology, and Liver Disease Franchise Continues ...